The ESMO 2023 Programme is now online!
A comprehensive educational and scientific programme will foster exchange and debate of translational cancer science, showcase first announcements of potentially practice changing data and stimulate multidisciplinary discussions to improve treatment options for our patients.
- To review and be updated on prevention, screening and early diagnosis of cancer
- To be updated on the latest breakthroughs in basic science, translational and clinical cancer research
- To analyze and understand the clinical perspective of the scientific advances in cancer biology, diagnostics, and new treatments
- To learn the optimal roles of novel diagnostics and treatments for patients with cancer
ESMO-MORA: The Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.